Literature DB >> 3128416

The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.

L Lemberger1, H Rowe, J C Bosomworth, J B Tenbarge, R F Bergstrom.   

Abstract

To determine the effect of fluoxetine on diazepam's pharmacokinetic and psychomotor responses, single oral doses of 10 mg diazepam were administered to six normal subjects on three occasions, either alone or in combination with 60 mg fluoxetine. Diazepam was given alone, after a single dose of fluoxetine, and after eight daily doses of fluoxetine. Psychometric data showed that fluoxetine had no significant effect on the psychomotor responses to diazepam. However, the pharmacokinetic data indicated a change in diazepam disposition after fluoxetine administration. Diazepam AUC was larger, the half-life was longer, and the plasma clearance was lower after fluoxetine administration, suggesting that fluoxetine inhibited the metabolism of diazepam. The reduced formation of an active metabolite, N-desmethyldiazepam, also suggested that fluoxetine inhibited diazepam's metabolism. The clinical implications of this pharmacokinetic drug-drug interaction are minor because psychomotor responses were unaffected and offsetting changes in the kinetics of diazepam and its metabolite occurred. Dosage modification of either fluoxetine or diazepam is unlikely to be necessary.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128416     DOI: 10.1038/clpt.1988.52

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

1.  Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine.

Authors:  T A Lasher; J C Fleishaker; R C Steenwyk; E J Antal
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Maintenance time of sedative effects after an intravenous infusion of diazepam: a guide for endoscopy using diazepam.

Authors:  Mitsushige Sugimoto; Takahisa Furuta; Akiko Nakamura; Naohito Shirai; Mutsuhiro Ikuma; Shingen Misaka; Shinya Uchida; Hiroshi Watanabe; Kyoichi Ohashi; Takashi Ishizaki; Akira Hishida
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

Review 3.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 4.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 5.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 6.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of fluoxetine.

Authors:  A C Altamura; A R Moro; M Percudani
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

Review 9.  Drug therapy for geriatric depression.

Authors:  R Bressler; M D Katz
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

10.  In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.

Authors:  Sylvain Goutelle; Laurent Bourguignon; Nathalie Bleyzac; Johanna Berry; Fannie Clavel-Grabit; Michel Tod
Journal:  AAPS J       Date:  2013-01-15       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.